Portfolio company Abzena, a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, has signed a significant licensing deal for its novel site specific ThioBridge™ antibody drug conjugate (ADC) linker technology. The partner is a publicly listed US biotech company that is developing and commercialising oncology therapies, including ADCs.
Dr John Burt,CEO of Abzena commented:
“Signing a licence for ThioBridge™ with a large US biotech partner is a key milestone for us and a great endorsement of our proprietary technology and expertise.”
“Through the research collaboration, our scientists have built a strong working relationship with our partner and have demonstrated the value of the ThioBridge™ technology in creating novel ADCs. We look forward to continuing to work together as this ADC progresses to and through clinical development.”